Compare BMEA & TOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | TOUR |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.9M | 87.0M |
| IPO Year | 2021 | 2014 |
| Metric | BMEA | TOUR |
|---|---|---|
| Price | $1.03 | $0.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.71 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 118.9K |
| Earning Date | 11-04-2025 | 12-05-2025 |
| Dividend Yield | N/A | ★ 4.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $75,532,120.00 |
| Revenue This Year | N/A | $12.27 |
| Revenue Next Year | N/A | $10.18 |
| P/E Ratio | ★ N/A | $21.97 |
| Revenue Growth | N/A | ★ 7.57 |
| 52 Week Low | $0.87 | $0.70 |
| 52 Week High | $7.46 | $1.17 |
| Indicator | BMEA | TOUR |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 42.33 |
| Support Level | $0.87 | $0.70 |
| Resistance Level | $1.12 | $0.77 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.93 | 38.91 |
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.